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Abstract
Objectives The objectives are to examine the reproducibility
of functional MR imaging in children with solid tumours
using quantitative parameters derived from diffusion-
weighted (DW-) and dynamic contrast enhanced
(DCE-) MRI.
Methods Patients under 16-years-of age with confirmed
diagnosis of solid tumours (n=17) underwent free-
breathing DW-MRI and DCE-MRI on a 1.5 T system,
repeated 24 hours later. DW-MRI (6 b-values, 0-
1000 sec/mm2) enabled monoexponential apparent diffu-
sion coefficient estimation using all (ADC0-1000) and
only ≥100 sec/mm2 (ADC100-1000) b-values. DCE-MRI
was used to derive the transfer constant (Ktrans), the
efflux constant (kep), the extracellular extravascular vol-
ume (ve), and the plasma fraction (vp), using a study
cohort arterial input function (AIF) and the extended
Tofts model. Initial area under the gadolinium enhance-
ment curve and pre-contrast T1 were also calculated.
Percentage coefficients of variation (CV) of all parame-
ters were calculated.
Results The most reproducible cohort parameters were
ADC100-1000 (CV=3.26 %), pre-contrast T1 (CV=6.21 %),
and Ktrans (CV=15.23 %). The ADC100-1000 was more repro-
ducible than ADC0-1000, especially extracranially (CV=
2.40 % vs. 2.78 %). The AIF (n=9) derived from this paedi-
atric population exhibited sharper and earlier first-pass and
recirculation peaks compared with the literature’s adult popu-
lation average.
Conclusions Free-breathing functional imaging protocols in-
cluding DW-MRI and DCE-MRI are well-tolerated in chil-
dren aged 6 - 15 with good to moderate measurement
reproducibility.
Key Points
• Diffusion MRI protocol is feasible and well-tolerated in a
paediatric oncology population.
• DCE-MRI for pharmacokinetic evaluation is feasible and
well tolerated in a paediatric oncology population.
• Paediatric arterial input function (AIF) shows systematic
differences from the adult population-average AIF.
• Variation of quantitative parameters from paired functional
MRI measurements were within 20 %.
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Abbreviations
ADC Apparent diffusion coefficient
AIF Arterial input function
CI Confidence interval
CV Coefficient of variation
DCE-
MRI
Dynamic contrast enhanced magnetic resonance
imaging
DW-MRI Diffusion-weighted magnetic resonance imaging
GRAPPA Generalised autocalibrating partially parallel ac-
quisition acceleration
IAUGC Initial area under the gadolinium curve
MRI Magnetic resonance imaging
PNET Primitive neuroendocrine tumour
ROI Region of interest
Introduction
Development of anti-cancer therapeutics targeted to specific
biological pathways, involved in tumour growth and progres-
sion, and inducing cytostasis rather than substantial tumour
shrinkage, has led to a need for non-invasive biomarkers
reporting on drug action and tumour response beyond simple
radiological assessment based on lesion size. Improving sur-
vival rates of poor-prognosis childhood cancers via clinical
introduction of new molecularly targeted anti-cancer thera-
peutics, through trials incorporating imaging for proof-of-
target inhibition or predictive biomarkers, is a priority [1–3],
and will accelerate and improve the paediatric drug develop-
ment process.
Diffusion-weighted (DW) and Dynamic Contrast-
Enhanced (DCE) MRI are imaging-based techniques that
can monitor and predict a response to conventional and novel
targeted therapeutic agents in clinical trials [4–17]. DW-MRI
provides information on tissue cellularity, integrity of cellular
membranes, and tortuosity of the extracellular space. Malig-
nant tumours are usually hypercellular compared with their
tissues of origin, and, thus, show a low apparent diffusion
coefficient (ADC). DCE-MRI enables the assessment of pa-
rameters pertinent to the state of tumour vasculature by track-
ing the kinetics of an intravenously administered contrast
agent. DCE-MRI measurements can be obtained from param-
eters such as: the volume transfer constant between plasma
and extracellular space (Ktrans), the efflux rate constant be-
tween extracellular extravascular space and plasma (kep), the
fractional volume of extracellular extravascular space per unit
volume of tissue (ve), the fractional volume of blood plasma
per unit volume of tissue (vp), the initial area under the gado-
linium curve over 60 seconds after arrival of contrast agent
(IAUGC60), and the longitudinal relaxation time before ad-
ministration of contrast agent (pre-contrast T1).
While these functional imaging biomarkers have been ex-
tensively used in early clinical trials in the adult setting, there
is very little information in the paediatric population where,
due to the differences in vascular physiology and biology of
paediatric tumours, they may be different. There are also
important practical issues that make functional measurements
more challenging in children, including logistical difficulties,
movement during the procedure, and difficulties obtaining
intravenous access. Additionally, the rarity of the conditions
necessitate multicentre clinical trials, requiring additional
validation and quality assurance procedures. For a prospec-
tive study of parameter reproducibility – rather than param-
eter values – it is possible to include a diverse range of
pathologies, giving increased recruitment within a cohort
where cancer is rare, and increased generality of the repro-
ducibility assessment. Improved knowledge of reproducibil-
ity for functional imaging will guide further development
and incorporation as exploratory or secondary endpoints in
multi-centre phase I/II clinical trials of cancer therapeutics in
children, particularly those that have an antiangiogenic ef-
fect. Specifically, DCE-MRI and DW-MRI may demonstrate
proof-of-mechanism that anti-angiogenics cause changes in
tumour vasculature and tumour cellularity. In addition, tu-
mour imaging characteristics at study entry or changes in
tumour imaging characteristics early in therapy may be pre-
dictive biomarkers for objective response and clinical
benefit.
The purpose of this study is to examine the feasibility of
performing functional MRI in children with solid tumours by
evaluating the reproducibility of quantitative parameters de-




This prospective study was approved by the institutional re-
view board; prior written consent was obtained from each
child’s parent/legal guardian, with assent from each child. In-
clusion criteria were: patients (a) less than 16 years old, (b)
with confirmed diagnosis of a solid tumour, (c) with a mea-
surable target lesion (≥2 cm), and (d) requiring MRI as part of
their routine care. Exclusion criteria were patients with: (a)
general anaesthesia required for their scans, (b) renal function
impairment, (c) previous allergy to contrast, or contraindica-
tions to MRI, (d) lung metastases only, and (e) disease sites
that may result in substantial artefacts on the DCE-MRI and
DW-MRI studies.
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MRI studies
Imaging was performed with a 1.5 T Magnetom Avanto sys-
tem (Siemens Healthcare, Erlangen, Germany) using a
phased-array head coil (intra-cranial studies) or a phased-
array body coil (extra-cranial studies). DW- and DCE-MRI
was performed during the initial routine MRI, and repeated
after 24 hours.
Diffusion-weighted MRI
The free-breathing DW-MRI protocol used a multi-slice
single-shot echo-planar imaging sequence with: echo
time, 75 msec; repetition time, 3500 msec; matrix,
128×128 (interpolated to 256×256); 24 slices with
5 mm thickness; generalised autocalibrating partially
parallel acquisition acceleration (GRAPPA) factor
of two; spectral adiabatic inversion-recovery fat sup-
pression, and three signal averages. Six diffusion gra-
dients (b-values: 0, 50, 100, 300, 600, and 1000 sec/
mm2) were applied in three orthogonal directions and
averaged to provide isotropic trace-weighted images.
Total time for DW-MRI was 3 min 30 seconds. The
fields of view were 220×220 mm2 in the transverse
orientation (intra-cranial studies) and 300×300 mm2
in the coronal orientation (extra-cranial studies). The
central imaging slice was positioned through the centre
of the tumour.
Dynamic contrast-enhanced MRI
The free-breathing DCE-MRI protocol consisted of the
following:
i.) A proton density-weighted three-dimensional spoiled
gradient-echo sequence with: echo time, 0.95 msec;
repetition time, 3.00 msec; matrix, 128×128 (inter-
polated to 256×256); 14 partitions with 5 mm
thickness; GRAPPA factor of two; flip angle, 3°;
and ten signal averages. The DCE-MRI volume
was centred on the DW-MRI volume.
ii.) A dynamic T1-weighted acquisition with identical
parameters, except for a flip angle of 16°, and
one signal average. Eighty volumes at 3.23 seconds
each were acquired in approximately 4 minutes. At
the fifth volumetric acquisition, gadolinium-based
contrast agent (single dose, 0.1 mmol/kg) was
injected followed by 10 ml of saline. Magnevist®
was the contrast agent used initially, but it was
changed to Dotarem® following a change in local
policy regarding MR contrast agents. In children
without an implanted central line, injections were
performed using a power injector through a
peripherally-inserted intravenous cannula. The flow
rate varied between 1–3 ml/sec appropriate to the
cannula. A number (n=4) of patients had a
Hickman-type central line in place; to avoid an
additional invasive procedure in these children,
contrast was delivered manually into the central
line via a three-way tap by an expert radiologist
(D.M.K).
iii.) The sequence in i.) was repeated following the dynamic
acquisition, to allow subsequent conversion of signal
intensity to contrast agent concentration [18, 19]. Total
time for DCE-MRI was 6 minutes.
Patients were imaged twice, 24 hours apart without treat-
ment intervention, using the same imaging and injection
protocols.
Image analysis
Images were assessed and regions-of-interest (ROIs) were
drawn by an expert radiologist (D.M.K); ROIs were drawn
around the tumour for three central slices of the imaging vol-
ume, and in the matching slices of the repeat study. Data
processing to derive functional parameters was performed
offline by a postdoctoral research fellow experienced
(6 years) in DW- and DCE-MRI studies. DW-MRI analysis
was performed offline using ADEPT software (The Institute
of Cancer Research, London, UK). Apparent diffusion coef-
ficient values (ADC, 10-6 mm2/sec) were calculated using
Levenberg-Marquardt mono-exponential fitting with signal
intensities from: (i) all b-values (0, 50, 100, 300, 600,
and 1000 sec/mm2, ‘ADC0-1000’) and (ii) b-values ≥100 sec/
mm2 (100, 300, 600, and 1000 sec/mm2, ‘ADC100-1000’) on a
voxel-by-voxel basis.
DCE-MRI data processing was performed off-line using
MRIW software (The Institute of Cancer Research, London,
UK), using the same slices and ROIs as for the DW-MRI. The
proton-density weighted images acquired post-contrast were
used with the dynamically acquired T1-weighted images to
generate contrast agent concentrations on a per-voxel basis
[18, 19]. Relaxivities of Magnevist® and Dotarem® at 1.5 T
were taken to be 4.3 and 4.2 mM-1 sec-1, respectively. The
model-independent parameters evaluated were: (i) IAUGC60,
in mM.sec, and (ii) the pre-contrast T1, in seconds. Pharma-
cokinetic model analysis was performed using an extended
Tofts model and a population-averaged arterial input
function (AIF), measured from a subset of the study
cohort where a suitable ROI could be drawn along the
descending aorta on or near the central partition
(Fig. 1a). Dynamic signal intensities averaged over the
ROI were converted to contrast agent concentrations as
for the lesion data, and an empirical input function
model consisting of components describing the first
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pass, second pass, and equilibrium phases was fitted to
the data [20, 21]:
Cp tð Þ ¼ CB tð Þ⊗RM tð Þ þ CR t−tRð Þ þ CR t−tRð Þ⊗RE tð Þ; ð1Þ
where CB(t) models dispersion in the lungs, CR(t) describes
the recirculation phase with a delay tR, and both are modelled
with raised cosine functions [22]. RM(t) is an impulse response
modelling the mixing through the heart, given by RM(t)=αM
exp(−μMt) , and RE(t) is an impulse response modelling reflux
of contrast from the whole-body extra-vascular space: RE(t)=-
αEexp(−μEt). The input function is thus defined by eight pa-
rameters: aB, μB, μM (first pass phase), aR, μR, tR (second pass
phase), aE and μE (equilibrium phase). A population-averaged
paediatric AIF was constructed by taking the median of the
individual AIF parameters after accounting for variations in
haematocrit measured in individual patients. The DCE-MRI
model-dependent parameters evaluated were: (i) Ktrans, inmin-
1, (ii) kep, in min
-1, (iii) ve, and (iv) vp.
Statistical analysis
For each parameter, the results from voxels in the three
analysed slices were combined, and the median parameter
value was used in analysis of reproducibility. For model-
derived DCE-MRI parameters, values from non-enhancing
voxels (where post-onset signal intensities stay within one
standard deviation of the pre-contrast mean signal intensity)
were not included. The time required for post-processing (per-
formed offline on a laptop, 2.4 GHz processor, 8 GB RAM)
varied directly with the size of the tumour ROIs, from approx-
imately 20 seconds to 14 minutes (DCE-MRI) and 10 seconds
to 6.5 minutes (DW-MRI) for the smallest and largest tu-
mours, respectively. Baseline variability between repeat me-
dian parameters was assessed by calculating the coefficient of
variation (CV) and 95 % confidence interval (CI) limits using
log-transformed measurement values for: (i) intra-cranial, (ii)
extra-cranial, and (iii) combined cohorts.
Results
The study cohort comprised 17 patients with solid tumours
(eight intracranial, nine extracranial tumours) recruited be-
tween January 2010 and August 2013. Median patient age
was 11 years (range 6–15 years). Patient characteristics and
primary tumour classification are summarised in Table 1.
All patients were cooperative and tolerated the free-
breathing imaging protocol well. One patient did not return
for a repeat scan owing to logistical difficulties. DW-MRI data
in one patient suffered technical failure. Tumours in four pa-
tients did not exhibit contrast agent uptake (intracranial: ana-
plastic astrocytoma and thalamic high-grade glioma; and ex-
tracranial: intra-abdominal PNETand neuroblastoma stage 4).
Reproducibility values of the DW-MRI parameters were, thus,
analysed using 15 pairs of measurements (seven intracranial,
eight extracranial), and that of DCE-MRI parameters using 12
pairs of measurements (five intracranial, seven extracranial).
Nine study-specific, individual AIFs were obtained from
DCE-MRI. The cohort-averaged paediatric AIF is shown in
Fig. 1b together with an adult population-averaged AIF
refitted to the input function model in Eq. 1 [20, 23] with an
assumed haematocrit of 0.42. First-pass and recirculation
peaks were found to be sharper and to occur earlier in the
Fig. 1 (a) T1-weighted DCE-MR image at peak arterial enhancement in
the descending aorta with a region-of-interest (turquoise) used for
measurement of arterial input function overlaid. (b) Population-
averaged input functions obtained from a subset of children in this
study cohort (red) and from adult patients (blue) [20] fitted to an
empirical input function model C. The input function parameters are
summarised in Table 1. Only the first two minutes of the concentration-
time course data have been shown for display purposes
2644 Eur Radiol (2015) 25:2641–2650
paediatric AIF; parameters for the two population-averaged
AIFs are given in Table 2.
The coefficients of variation and 95 % CI limits for all
imaging parameters are summarised in Table 3. The most
reproducible DW-MRI and DCE-MRI parameters for the full
cohort were ADC100-1000 (CV=3.26 %), pre-contrast T1
(CV=6.21 %), and Ktrans (CV=15.23 %). The ADC100-1000
was found to be more reproducible than ADC0-1000, especially
extracranially (CV=2.40 % vs. 2.78 %).
Example ADC maps and mono-exponential curve fits for
ADC0-1000 and ADC100-1000 from intracranial and extracranial
tumour patients are shown in Figs. 2 and 3, respectively. The
IAUGC60 and Ktrans maps and contrast agent uptake curves
(same patients) are shown in Figs. 4 and 5.
Discussion
Functional imaging has the potential to provide imaging bio-
markers for proof-of-mechanism for angiogenesis inhibitors,
and to identify those patients more likely to respond to a given
therapy, as well as providing more physiological sensitivity
when assessing post-treatment response.
The range and specificity of available functional imaging
modalities allow improved characterisation of spatial differ-
ences in biological properties both within and between tu-
mours, though at the cost of lengthened imaging studies. Pae-
diatric MRI is particularly challenging, since children may not
lie still during the entire imaging protocol, find the noise and
confined space distressing, or may be unable to cooperate with
breath-holding instructions intended to minimise abdominal
motion artefacts as used with adults.
Despite the challenges involved, there is increasing use of
functional imaging in children with intracranial tumours, as
summarised by Peet et al. [24]. There are, however, still very
few reports of functional imaging studies in children with
extracranial tumours. Despite this paucity, there are studies
that report the potential of DW- and DCE-MRI biomarkers
for disease characterisation [25, 26] and response assessment
in various paediatric oncological settings. Rodriguez-
Gutierrez et al., evaluated serial DW-MRI to predict treatment
response in high-grade paediatric brain tumours and found
that responders exhibited a higher regional ADC increase
[27]. Guo et al., performed DCE-MRI in children with newly
diagnosed, non-metastatic osteosarcoma treated on a phase 2
trial (NCT001456390) [28], finding DCE-MRI derived pa-
rameters were potential early prognostic factors for event-
free and overall survival. Recently, Navid et al., published
the results of a phase I and clinical pharmacology study of
bevacizumab, sorafenib, and low-dose cyclophosphamide in
children and young adults with refractory/recurrent extracra-
nial solid tumours [29]; both groups of study patients exhibit-
ed a rapid decrease in Ktrans and vp in the first 7 days after
treatment initiation. Such results demonstrate the emerging
roles of functional MR imaging markers for assessing and
predicting treatment response in children with cancer, and
their potential contribution to the development of stratified
treatment regimens.
Baseline reproducibility values of the functional MR pa-
rameters are important measures of consistency and reliability
that should be evaluated. Several studies have investigated the
reproducibility of DW- and DCE-MRI derived parameters in
adults [10, 12, 30]; given the added challenges when imaging
children, arising from both logistical and physiological differ-
ences, reproducibility should be investigated specifically for
this cohort.
In this present study functional MR imaging, repeated fol-
lowing 24 hours without treatment intervention, was per-
formed in a paediatric cohort (6 to 15 years-of-age) to assess
Table 1 Patient characteristics and primary tumour classification
Sex/Age Pathology
Intracranial tumour
1 F/8 Anaplastic astrocytoma
2 M/7 Primitive neuroectodermal tumour
3 M/10 Glioblastoma multiforme
4 M/11 High grade glioma
5 F/9 Glioblastoma multiforme
6 M/8 Glioblastoma multiforme




10 M/13 Spindle cell sarcoma
11 F/12 Ganglioneuroblastoma
12 M/14 Rhabdomyosarcoma
13 M/15 Sacral myxopapillary ependymoma
14 M/12 Intra-abdominal primitive neuroectodermal tumour
15 M/6 Neuroblastoma
16 M/13 Rhabdomyosarcoma
17 M/14 Neuroendocrine tumour
Table 2 Summary of input function model parameters [21] for the
population-averaged adult and paediatric arterial input functions
Input function parameters Adult Paediatric





Second-pass parameters aR (mM) 4.96 8.19
μR (min
-1) 9.48 32.0
tR (min) 0.0943 0.209
Equilibrium phase parameters aE (mM) 25.4 84.3
μE (min
-1) 0.169 0.179
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the reproducibility of the derived parameters. All seventeen
children who participated in the study were able to cooperate
throughout the entire imaging protocol, including injections of
contrast agent and saline flush. The quality of data obtained
allowed DW-MRI and DCE-MRImodel fitting on a voxel-by-
voxel basis to generate parametric maps, with parameter re-
producibility values comparable to those achieved in adult
cohorts [12, 30]. The diversity of tumours present in the co-
hort adds to the generality of the result, with both extracranial
and intracranial tumour subgroups presenting similar coeffi-
cients of variation.
Whole cohort ADC reproducibility was found to be
better when excluding the two lowest b-values in the
mono-exponential fitting procedure, compared to using
all b-values; this difference was also present for the
extracranial tumour cohort, suggesting that fitting a
mono-exponential model for all b-values results in
ADC measures that will be biased by the lower b-
value data points. The curve fits shown in Figs. 2 and
3 clearly illustrate this bias. The use of a bi-exponential
model with Bslow^ and Bfast^ diffusion components
arising from an optimised diffusion protocol may be
more informative, as well as better reflecting the prop-
erties of specific tumour types, and should be explored.
For DCE-MRI measurements, we employed a 3-D volu-
metric protocol with good spatial and temporal resolutions.
The dynamic temporal resolution employed (~3 s) not only
helped to minimise motion artefacts but also helped to capture
the contrast uptake curves in the tumour and the descending
aorta (where signal changes occur rapidly). Using the contrast
uptake curves from the descending aorta, it was possible to
construct a paediatric population AIF (Fig. 1b), observed to
have features distinct from those seen in an adult population
[23] and consistent with the relatively high rate of circulation
seen in children. Although limited patient numbers preclude
investigation of AIF variations with age in this present study,
Table 3 Reproducibility values of DW-MR imaging and DCE-MR imaging parameters
Coefficient of Variation (%), 95 % confidence interval limits in parentheses
DW-MRI parameters Intra-cranial (n=7) Extra-cranial (n=8) Intra- and extra-cranial (n=15)
ADC0-1000 3.92 (-7.4, 8.0) 2.78 (-5.3, 5.6) 3.74 (-7.1, 7.6)
ADC100-1000 4.09 (-7.7, 8.4) 2.40 (-4.6, 4.8) 3.26 (-6.2, 6.6)
DCE-MRI parameters Intracranial (n=5) Extracranial (n=7) Intracranial and extracranial (n=12)
Pre-contrast T1 7.99 (-14.5, 16.9) 5.19 (-9.7, 10.7) 6.21 (-11.5, 12.9)
IAUGC60 9.38 (-16.8, 20.1) 11.71 (-20.5, 25.7) 12.77 (-22.1, 28.3)
Ktrans 13.58 (-23.3, 30.3) 16.79 (-27.9, 38.7) 15.23 (-25.7, 34.5)
kep 21.74 (-34.4, 52.4) 19.74 (-31.8, 46.7) 19.60 (-31.7, 46.3)
ve 20.05 (-32.2, 47.6) 17.48 (-28.8, 40.5) 18.56 (-30.3, 43.4)
vp 50.73 (-60.9, 155.5) 16.29 (-27.2, 37.3) 36.24 (-49.8, 99.1)
Fig. 2 (a) ADC100-1000 map from a 10-year-old boy with glioblastoma
multiforme in the left frontal lobe. (b) Example mono-exponential curve
fits using signal intensities at b=0 – 1000 sec/mm2 (blue) and b=100 –
1000 sec/mm2 (red) from a single pixel in the tumour. The calculated
ADC value for the two fits were 1402×10-6 mm2/sec and 1228×10-
6 mm2/sec, respectively
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the differences observed between the paediatric and adult pop-
ulation AIFs highlight the importance of conducting such in-
vestigations in the future. Additionally, it is important to opti-
mise the injection protocol in patients with an implanted cen-
tral venous line to minimise the variability observedwith hand
injections [20].
Pre-contrast T1 was found to be a robust parameter
with the best reproducibility (CV=6.21 %). This param-
eter is used in the conversion of signal intensity to
contrast agent concentration for quantitative DCE-MRI
data analysis, but it is also a potential marker for treat-
ment response [31, 32]. There is a consensus that
IAUGC60 and Ktrans should be used as quantitative end-
points for DCE-MRI when used in the development of
anti-angiogenic and anti-vascular agents [33, 34], with a
recent report on DCE-MRI quantification supporting a
CV of less than 20 % for these parameters [35]. In our
study, the CV of IAUGC60 and Ktrans for the whole
cohort were 12.77 % and 15.23 %, respectively. The
reproducibility of other DCE-MRI derived parameters
ranged between 12.8 to 19.6 % except for vp for the
whole cohort (36.24 %). It is interesting that the DCE-
MRI parameters generally expressed a higher variability
than those from DW-MRI, which may reflect either ad-
ditional complexities of administering exogenous con-
trast or, given that the most reproducible DCE-MRI pa-
rameters were model-independent, the inherent difficulty
in modelling a complex process.
There are several limitations to this study. Firstly,
the number of patients involved in the study is small
(recruitment of n=17 was completed over 3.5 years) as
patients were asked to undergo a second MRI research
examination. This reflects the ethical and logistical
chal lenges of research involving chi ldren and
Fig. 3 (a) ADC100-1000 map from a 13-year-old boy with a low grade
spindle cell sarcoma attached to the right chest wall. The signal void seen
in the top left region is due to a saturation band placed over the heart to
avoid propagation of artefacts due to cardiac motion. (b) Example mono-
exponential curve fits using signal intensities at b=0 – 1000 sec/mm2
(blue) and b=100 – 1000 sec/mm2 (red) from a single pixel in the
tumour. The calculated ADC value for the two fits were 1626×10-
6 mm2/sec and 1221×10-6 mm2/sec, respectively
Fig. 4 Parametric maps of (a) IAUGC60 and (b) Ktrans from the same patient in Fig. 2. (c) Contrast agent concentration-time course from a voxel in the
tumour (circles) and the corresponding curve fit to the data (solid curve)
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emphasises the importance of multi-centre collaboration
to increase recruitment. The small cohort, and, there-
fore, limited numbers for the range of tumours repre-
sented, restricts the conclusions that can be drawn
about specific tumour types, though functional param-
eter reproducibility is more dependent on factors aris-
ing from tumour location, imaging set-up, and acquisi-
tion parameters than from lesion type. Secondly, a
population-averaged AIF for pharmacokinetic model-
ling of DCE-MRI data may mask differences arising
from true physiological variations. Obtaining a study-
specific AIF, however, is a well-documented challenge;
in our experience, it was not always possible to include
an artery in the central partitions of the imaging vol-
ume. Therefore, using a population-averaged AIF was a
pragmatic solution for this present study. Wang et al.,
have shown that it is reasonable and practical to use a
limited-population-based average AIF for pharmacoki-
netic modelling of osteosarcoma DCE-MRI data from
a large population when it is not possible to measure
every individual AIF [36]. Thirdly, we have not includ-
ed younger children requiring sedation or general an-
aesthesia for their examinations, due to the ethical
challenges involved in performing repeated sedation
solely for research purposes.
In conclusion, this study has demonstrated that a
free-breathing protocol including diffusion-weighted
and dynamic contrast-enhanced MR imaging in children
aged between 6 and 15-years-old is feasible and well-
tolerated, and that reproducible functional parameters
can be obtained. The non-invasive nature of such imag-
ing makes this approach particularly attractive for use in
a paediatric population. Findings of this pilot study will
support the incorporation of DW- and DCE- MRI in
paediatric phase I-II clinical trials of new molecularly
targeted agents, particularly those targeting VEGF/
VEGFR and other angiogenesis pathways.
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